[1] WHO. Draft landscape of COVID-19 candidate vaccines 9 September2020[EB/OL].[2020-09-22]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. [2] Hawkes RA.Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls[J]. Aust J Exp Biol Med Sc, 1964, 42(4): 465-482. [3] Halstead SB, O'Rourke EJ. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody[J]. The Journal of Experimental Medicine, 1977, 146(1): 201-217. [4] Halstead SB.Dengue haemorrhagic fever-a public health problem and a field for research[J]. Bull World Health Organ, 1980, 58(1): 1-21. [5] Sangkawibha N, Rojanasuphot S, Ahandrik S, et al.Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand: I. the 1980 outbreak[J]. Am J Epidemiol, 1984, 120(5): 653-669. [6] Huisman W, Martina BE, Rimmelzwaan GF, et al.Vaccine-induced enhancement of viral infections[J]. Vaccine, 2009, 27(4): 505-512. [7] Takada A, Watanabe S, Okazaki K, et al.Infectivity-enhancing antib-odies to Ebola virus glycoprotein[J]. Virol, 2001, 75(5): 2324-2330. [8] Takada A, Feldmann H, Thomas G, et al.Antibody-dependent enhancement of Ebola virus infection[J]. Virol, 2003, 77(13): 7539-7544. [9] Wan YS, Shang J,Sun SH, et al.Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J]. Virol, 2020 (5): 94. [10] Lambert PH, Ambrosino DM, Andersen SR, et al.Consensus summary report for CEPI/BC March 12-13, 2020 meeting: assessment of risk of disease enhancement with COVID-19 vaccines[J]. Vaccine, 2020, 38(31): 4783-4791. [11] Hadinegoro SR, Arredondo-García JL, Capeding MR, et al.Efficacy and long-term safety of a dengue vaccine in regions of endemic disease[J]. N Engl J Med, 2015, 373(13): 1195-1206. [12] Katzelnick LC, Gresh L, Halloran ME, et al.Antibody-dependent enhancement of severe dengue disease in humans[J]. Science, 2017, 358(6365): 929-932. [13] Wang TT, Sewatanon J, Memoli MJ, et al.IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity[J]. Science, 2017, 355(6323): 395-398. [14] Chin J, Magoffin RL, Shearer LA, et al.Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population[J]. Am J Epidemiol, 1969, 89(4): 449-463. [15] Openshaw PJ, Tregoning JS.Immune responses and disease enhancement during respiratory syncytial virus infection[J].Clinical Microbiology Reviews, 2005, 18(3): 541-555. [16] Vaccines(疫苗学). Sixth Edition[M] Page 1763, Chapter 55-Respi-ratory syncytial virus and parainfluenza virus vaccines, People's Medical Publishing House. [17] Rauh LW, Schmidt R.Measles immunization with killed virus vaccine. serum antibody titers and experience with exposure to measles epidemic. 1965[J]. Bull World Health Organ, 2000, 78(2): 226-231. [18] Philip MD, Nader R, Marshall , et al. Atypical exanthem following exposure to natural measles: Eleven cases in children previously inoculated with killed vaccine[J]. The Journal of Pediatrics, 1968, 72(1): 22-28. [19] Polack FP, Hoffman SJ, Crujeiras G, et al.A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles[J]. Nat Med, 2003, 9(9): 1209-1213. [20] Lin JT, Zhang JS, Su N, et al.Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine[J]. Antivir Ther, 2007, 12(7): 1107-1113. [21] Martina JE, Louder MK.A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial[J]. Vaccine, 2008, 26: 6338-6343. [22] Modjarrad K, Roberts CC, Mills KT, et al.Safety and immu- nogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1,open-label, single-arm, dose-escalation trial[J]. Lancet Infect Dis, 2019, 19(9): 1013-1102. [23] Arvin AM, Fink K, Schmid MA, et al.A perspective on potential antibody-dependent enhancement of SARS-CoV-2[J]. Nature, 2020, 584: 353-363. [24] Weiss RC, Scott FW.Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever[J]. Comp Immunol Microbiol Infect Dis, 1981, 4(2): 175-189. [25] Vennema H, Groot de RJ, Harbour DA, et al. Early death after feline Infectious peritonitis virus challenge due to recombinant vaccinia virus immunization[J]. Virol, 1990, 64(3): 1407-1409. [26] Liu L, Wei Q, Lin Q, et al.Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J]. JCI Insight, 2019, 4(4): 123158. [27] Yip MS, Leung NHL, Cheung CY, et al.Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus[J]. Virol, 2014,11:82. [28] Wang QD, Zhang LF, Kuwahara K, et al.Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates[J]. ACS Infect Dis, 2016 , 2(5): 361-376. [29] Tseng CT, Sbrana E, Yoshikawa NI, et al.Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus[J]. PLoS One, 2012, 7(4): e35421. [30] Yasui F, Kai C, Kitabatake M, et al.Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV[J]. Immunol, 2008, 181(9): 6337-6348. [31] Agrawal AS, Tao X, Algaissi A, et al.Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J]. Hum Vaccin Immunother, 2016, 12(9): 2351-2356. [32] Yin Huajing, Wang Yin,Wu Shuang, et al.Considerations on the evaluation of non-clinical study on the SARS-CoV-2 vaccine[J]. Chinese Journal of Biologicals(中国生物制品学杂志), 2020, 33(4): 486-488. |